About Us
Opimend Ltd, based in the Weizmann Science Park, Israel, is a fully owned subsidiary of Drug Rediscovery Group Ltd (DRG). DRG redefines drug repurposing by focusing on established drugs that have established clinical proof of efficacy.
Opimend’s sole focus is to develop repurposed drugs that are able to play critical roles in solving the opioid crisis. Through Opimend’s consolidated pipeline for safe and established drugs, we are poised to have ready-to-market drugs starting from Q4 of 2020.
Moshe Rogosnitzky
CEO
-
Multi-disciplinary scientist, pragmatic researcher and insightful medical consultant with multi-sector expertise:
Oncology, Inflammatory Bowel Disease, Ophthalmology, Hemostasis, Androgenic alopecia, Insomnia, Viral diseases and Pain conditions. -
Clinical:
Heads Israel’s first personalized medicine consultancy founded in 2001. -
Drug Development:
Serial innovator of 25+ patented/patent-pending drug discoveries, with several discoveries licensed. -
Scientific Research:
Author of 25+ papers in recognized medical publications. -
Patient & Physician Education:
Established a leading online drug-repurposing consumer and physician education platform, which reaches 500,000+ users annually.
Bracha Obermeister
Director
- IT & Medical Information Management in governmental organization and private industry.
-
Information Technology:
Bracha has 15 years of experience in IT development and team leadership for: Israel National Insurance Institute, IDT, Actus-Imago and AT&T. -
Medical Management & Education:
Four years of experience managing a personalized medicine consultancy and patient/physician educational tools. -
Drug Repurposing:
Corporate management roles at Drug Rediscovery Group Ltd, Vigorous Solutions Ltd, Ocular Discovery Ltd, and Opimend Ltd.
Advisors & Development Partners
Horn & Co
DocuChem